1.Research progress of epigenetics therapy for lung cancer
Chinese Journal of Clinical Oncology 2013;(24):1570-1572
The five-year survival rate of lung cancer, one of the cancers with higher morbidity and death rate, is less than 15%. Studies have shown that the occurrence of lung cancer is related to many factors in which epigenetics is an important one. In recent years, with the successful clinical application of epigenetic therapy drugs such as methylation transferase and histone deacetylase inhibi-tors that can enhance the sensitivity of chemotherapy, epigenetics has become a research hotspot. This paper briefly introduces the re-search progress in DNA methylation, acetylation, and cancer chemotherapy sensitivity in lung cancer diagnosis and treatment.
2.Effect of 5-Aza-CdR with MS275 on growth and expression of DNMT1 protein in cell lines of non-small cell lung cancer
Bangqing LIU ; Jiaqiang LUAN ; Xiaolin SUN ; Jian BAI ; Jianfei SONG ; Zhenzong DU
The Journal of Practical Medicine 2016;32(13):2105-2108
Objective To explore the characteristics and biological functions of epigenetic treatment to DNMT1 expression in NSCLC cell lines. Methods Lung cancer cells were divided into 4 groups , and drugs with different concentrations. The effect of epigenetic treatment on NSCLC cell line was detected by CCK-8 and MTT. The effect of epigenetic treatment on the expression of DNMT1 in NSCLC cell line was detected by Western blot. Results CCK-8 and MTT assay showed that treatment with 5-Aza-CdR and MS-275 inhibited the proliferation of NSCLC cells. Western blot showed that treatment with 5-Aza-CdR and MS-275 inhibited the DNMT1 expression in NSCLC cells. Conclusion The expression of DNMT1 gene in the NSCLC cell lines may be suppressed effectively by epigenetic treatment , and the gene may inhibit the proliferation and growth of NSCLC cell lines.